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Dose fractionation has been proposed as a method to improve the therapeutic ratio of radioimmunotherapy (RIT). This study
compared a single administration of 7.4MBq
131I-anti-CEA antibody given on day 1 with the same total activity given as fractionated
treatment: 3.7MBq (days 1 and 3), 2.4MBq (days 1, 3, and 5) or 1.8MBq (days 1, 3, 5, and 8). Studies in nude mice, bearing the
human colorectal xenograft LS174T, showed that increasing the fractionation significantly reduced the efficacy of therapy.
Fractionation was associated with a decrease in systemic toxicity as assessed by weight, but did not lead to any significant decrease in
acute haematological toxicity. Similarly, no significant decrease in marrow toxicity, as assessed by colony-forming unit assays for
granulocytes and macrophages (CFUgm), was seen. However, there was a significant depression of CFUgm counts when all treated
animals were compared with untreated controls, suggesting that treatment did suppress marrow function. In conclusion, in this
tumour model system, fractionated RIT causes less systemic toxicity, but is also less effective at treating tumours.
British Journal of Cancer (2008) 99, 632–638. doi:10.1038/sj.bjc.6604511 www.bjcancer.com
Published online 5 August 2008
& 2008 Cancer Research UK
Keywords: radioimmunotherapy; anti-CEA antibody targeting; colorectal cancer; dose fractionation;
131I; CFUgm
                                         
Radioimmunotherapy (RIT) uses antibodies to deliver biologically
targeted radiotherapy and has achieved considerable success in the
treatment of the lymphomas and leukaemias (Press et al, 1995;
DeNardo et al, 1999; Kaminski et al, 2000; Burke et al, 2002).
However, success in the treatment of the common epithelial
tumours has been less impressive. For example, in a recent review
of RIT colorectal cancer looking at a large number of phase I/II
clinical studies, only modest activity has been seen (Koppe et al,
2005). In external beam radiotherapy (EBRT), fractionation,
dividing the total therapy dose into a number of smaller doses,
is an established practise and reduces late normal tissue toxicity.
This approach allows for significant increases in the total radiation
dose that can be delivered, improving the therapeutic ratio (Hall,
1985). Another beneficial effect of fractionation is tumour
shrinkage during therapy leading to a process of tumour
revascularisation and re-oxygenation (Hall, 1985). Fractionation
of RIT has been proposed as a method for improving its
therapeutic ratio (DeNardo et al, 2002).
To build on earlier work, the purpose of this study was to
investigate the therapeutic efficacy and toxicity of
131I-labelled
A5B7, a monoclonal antibody binding to carcinoembryonic antigen
(CEA), as either a single treatment or as part of a fractionated
regimen in nude mice bearing CEA-expressing LS174T xenografts.
A previous study using
131I-labelled A5B7 fragments did not
demonstrate a therapeutic advantage to fractionation, although
only a single fractionation regime (1 vs 3 doses) was investigated
and no direct assessment of haematological toxicity was made
(Pedley et al, 1993). In this study, a range of fractionation regimes
have been investigated and a detailed assessment made of both
systemic and haematological toxicities. The latter comprised
measurement of both acute changes in mature blood indices and
also an assessment of haematopoietic stem cell function.
MATERIALS AND METHODS
Antibody and radiolabeling
The monoclonal antibody A5B7 used in this study has been
described previously (Rogers et al, 1984) and has been used pre-
clinically and clinically for the RIT of CEA-expressing tumours
(Begent et al, 1989; Pedley et al, 1991, 1993, 1994, 2001; Lane et al,
1994). The antibody was radiolabelled on day 1 using the
chloramine-T method (Greenwood and Hunter, 1963) at a ratio
of 5MBq
131I to 1mg antibody and sterilised by passage through a
0.22mm acrodisc filter. Carcinoembryonic antigen binding was
assessed on days 1 and 8 using a CEA-binding column, and
stability of the radioimmunoconjugate over the course of the
experiment was assessed using thin-layer chromatography. All
experiments were in compliance with the UK Coordinating
Committee on Cancer Research Guidelines for the Welfare of
Animals in Experimental Neoplasia.
Animal model
The human colorectal adenocarcinoma cell line LS174T grows as a
moderate-to-poorly differentiated CEA-producing adenocarcinoma
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swith small glandular acini (Tom et al, 1976), and was used
to develop a tumour xenograft in the flanks of female MF1 nude
(nu/nu) mice by subcutaneous implantation of small tumour pieces
(B1mm
3). At the initiation of the experiments, mice were aged
2–3 months and weighed 23–27g. For all studies, the mice were
given food and water ad libitum. Water contained 0.1% potassium
iodide to block thyroid uptake of iodine.
Biodistribution studies
Detailed biodistribution studies have previously been performed
using
131I-A5B7 in both humans and this human xenograft model
(Lane et al, 1994; Pedley et al, 1991, 2001). A limited biodistribu-
tion study was performed for this experiment before the therapy
studies to confirm selective tumour localisation and retention,
and also the absence of significant normal tissue uptake. Anti-
body biodistribution was assessed by administering 1.8MBq of
131I-labelled radiolabelled antibody by tail vein injection into mice
bearing LS174T xenografts (tumour volume was approximately
0.75cm
3). At 24 and 48h, the animals (n¼4 mice per group)
were bled and liver, kidney, lung, muscle, colon, spleen, and
tumour removed for comparative activity assessment using a LKB
Wizard (Pharmacia, Milton Keynes, UK) gamma counter. Results
are expressed as percentage injected dose per gram of tissue
(% IDg
 1).
Therapy studies
To determine an appropriate fractionation schedule, a preliminary
series of single therapy experiments were performed in tumour-
bearing mice, with administered activities ranging from 1.8 to
11.1MBq. After therapy, tumour growth and acute haematological
toxicity were assessed as described above. On the basis of these
studies, a total activity of 7.4MBq was chosen for the fractionated
study, as this was associated with significant growth delay and
measurable white cell toxicity. Experiments commenced 7–10 days
after passaging when the tumours were in exponential growth and
had reached 0.1–0.2cm
3 in size. Groups of six mice received
radioactivity delivered as a single administration of 7.4MBq (day
1) or the same total activity divided into 2, 3, or 4 fractions of
3.7MBq (days 1 and 3), 2.4MBq (days 1, 3, and 5), or 1.8MBq
(days 1, 3, 5, and 8); control mice underwent tail vein injection of
normal saline. Formulation of the fractionated activities was
effected by diluting radiolabelled antibody made up on day 1 with
normal saline for each treatment, taking into account of radio-
active decay.
Tumours were measured every 2–3 days and mice were culled
by cervical dislocation when the tumour volume reached 1.5cm
3.
Tumour measurements were carried out in three dimensions
(length, width, and height), and the tumour volume was estimated
as length width height/2 (Looney et al, 1973).
Toxicity studies
Therapy toxicity was assessed by a number of indices. Systemic
toxicity was assessed by animal weights, with animals weighed on
the day of antibody injection and every 2–3 days thereafter. Acute
and late haematological toxicity was assessed using full blood
counting and assays of early progenitor cell function. Mice
underwent weekly removal of 25ml of whole blood for 1 month
after the initiation of therapy. After dilution in physiological
media, this blood was analysed using an automated haemo-
cytometer (Advia 120, Bayer Diagnostics, Tarrytown, NY, USA) to
give a haemoglobin level and white cell and platelet counts. Upon
killing, marrow was taken from the mouse femurs to perform
colony-forming unit assays for granulocytes and macrophages
(CFUgm). Using aseptic technique, a superficial incision was made
into the lower abdomen of the mice to pierce the skin. Subsequent
removal of the skin of the lower limbs and a limited dissection of
soft tissue from the femur was then performed to expose the knee
and hip joints. An incision was then made through the proximal
femur at the hip joint and just proximal to the knee. The marrow
contents were flushed from the marrow cavity using 2ml of
phosphate-buffered saline and a 25-gauge needle. This cell
suspension was then diluted in 3% acetic acid to lyse red blood
cells and the mononuclear cells counted using a haemocytometer.
Cells (10
5) were mixed thoroughly with growth medium (Metho-
cultt CFU-GM, StemCell Technologies, London, UK), and
incubated at 371C for 7 days in a humidified chamber with 5%
CO2. Colonies were counted using an inverted microscope with a
similar method applied to age-matched controls.
Statistics
Using the SPSS statistics package, the Kaplan–Meier analysis was
used to assess the survival of the different treatment groups with a
log-rank test to estimate any differences. Other intergroup analyses
were performed using either a Mann–Whitney U-test to compare
two groups or a one-way ANOVA where multiple comparisons
were made.
RESULTS
Radiopharmaceutical purity
There was a small increase in the proportion of free nuclide from
less than 0.5% at day 1 to 5.9% at day 7.
Antibody binding
Radiolabelled antibody was stored at 41C in phosphate-buffered
saline and antibody binding was assessed on days 1 and 7 using a
CEA-binding column. This revealed a modest decrease in binding
efficiency over the course of the experiment, falling from 86 to
70%. Radiopharmaceutical quality control was carried out by thin
layer chromatography.
Accuracy of repeated therapy administration
To check the accuracy of dilution and decay calculations, serial
gamma counter measurements of radiation delivery were taken on
each day of administration and revealed a high degree of
consistency in actual administered activity for the fractionated
therapies, with mean administered activity of 98.4% of baseline
with a standard deviation of 3.5%.
Biodistribution studies
Figure 1 shows the biodistribution of labelled antibody in groups
of four mice given 1.8MBq of
131I A5B7, which confirmed tumour
localisation and clearance from normal tissue. At 24h, 21.6%
(±6.8) of injected activity was found in the tumour, whereas blood
activity had already fallen to 5.3% (±2.7) and levels in other
normal tissues were even lower. At 48h, there was good retention
of activity within tumour at 17.5% (±11.4) of injected activity,
whereas blood activity had fallen further to 3.3% (±3.46).
Therapy studies
In the control group, exponential growth continued in all but one
animal, whereas a short period of continued tumour growth was
seen in all treated animals, followed by a reduction in tumour size
before re-growth (Figure 2). The period of tumour growth
inhibition was directly related to the activity of individual
therapies, with cures seen in five of the mice receiving a dose of
1 7.4MBq and two of the mice receiving 2 3.7MBq, but none of
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sthe mice in the other treatment groups during the observation
period of 230 days, at which point the experiment was terminated.
The Kaplan–Meier method has been used to display the
cumulative probability of mice surviving each of the treatment
regimes and is shown in Figure 3i. The log rank was applied to test
the null hypothesis that there was no difference in survival between
the treatment groups and revealed that there were significant
differences in survival between the different test groups. Group 1,
receiving a single administration of 7.4MBq (mean survival 190
days) had a significantly improved survival over all other
treatment groups with the exception of the 3.7MBq 2 group
(mean survival 118 days). No significant difference was found
when the other treatment groups were compared with each other,
but all the treatment groups had a significant survival advantage
over the control group and are shown inFigure 3ii.
Toxicity
Systemic toxicity: weight Control mice gained weight steadily
during the course of the experiment, whereas weight gain was
slower in all of the treatment groups (Figure 4i). A decrease of 10%
in body mass was seen in two of the animals in the 7.4MBq 1
group, and a single animal in both the 3.7MBq 2 and
1.8MBq 4 groups. The mean nadir weight for each group is
shown in Figure 4ii and analysis using a one-way ANOVA revealed
a significant difference between the groups (P¼0.033). Ad hoc
testing demonstrated a significant decrease in body mass for the
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Figure 3 (i) The Kaplan–Meier plot showing the difference in survival of
untreated and treated mice receiving 7.4MBq of
131I-A5B7 administered as
either a single therapy dose or multiple fractions. (ii) Mean survival times
assessed by the log-rank method.
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Figure 1 Distribution of
131I-labelled A5B7 at the 24 and 48h time
points (with associated standard deviations) in the tissues of mice bearing
LS174T xenografts (n¼4 at each time point).
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Figure 2 Individual tumour growth assessed using serial three-dimen-
sional measurements of tumour size to estimate tumour volume.
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s7.4MBq group compared with controls (P¼0.039), suggesting
increased systemic toxicity in this group.
Acute blood toxicity Owing to rapid tumour progression in the
control group, only a single untreated control mouse was available
for comparison with the therapy arms after day 8, and this data
have therefore been excluded from the statistical analysis. Mean
blood indices over time for each of the therapy groups are shown
in Figure 5. To detect any differences between the blood counts as
a result of therapy, the mean area under the curve (AUC) was
calculated for each of the therapy groups and a one-way ANOVA
was performed to look for differences between them. No
significant differences between the mean AUC was found for
haemoglobin (P¼0.302), platelets (P¼0.598), or total white cell
count (P¼0.763). Similarly, the acute nadir counts were also
analysed in the same way and revealed no significant difference
between any of the treatment groups for haemoglobin (P¼0.688),
platelets (P¼0.256), or total white cell count (P¼0.505).
Marrow progenitor cell toxicity Femoral marrow harvesting was
undertaken in therapy mice at the time of killing (with the
exception of the control group) and also in age-matched controls,
and used to perform CFUgm or macrophages and granulocytes.
Samples were tested for all the groups except for the 7.4MBq
group, where a number of samples failed as a result of technical
problems. Colony counts per 10
5 plated mononuclear cells are
shown with their respective age-matched controls in Figure 6i.
One-way ANOVA was used to look for differences in colony counts
between any of the treatment or control groups and revealed no
significant differences (P¼0.795, 0.865, respectively). A Mann–
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Figure 4 (i) Mean animal weights over time expressed as a percentage of baseline weight (±s.d.). (ii) Mean nadir weights as a percentage of baseline
weight (±95% CI).
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sWhitney U-test was also performed to analyse differences between
the colony counts in each of the treatment groups and their
respective age-matched controls and revealed no significant
differences for the 2 3.7, 3 2.4 or 4 1.8MBq groups
(P¼0.275, 0.513, and 0.275, respectively). Test data were subse-
quently pooled to look for any differences between the treated and
non-treated animals and are shown in Figure 6ii. A statistically
significant reduction in colony-forming units was found between
the treated and untreated animals using both t-test and the Mann–
Whitney U-test (P¼0.005 and 0.011, respectively).
DISCUSSION
Owing to the high incidence of neutralising antibody formation
seen using murine antibodies, most RIT to date has been
performed using single therapy schedules. However, with the
advent of chimeric and humanised antibodies of reduced
immunogenicity, repeated therapy with RIT is now possible.
Given the benefits seen from fractionation in EBRT, it has similarly
been proposed as a method to improve the therapeutic ratio of
RIT. However, a simple extrapolation from EBRT is not possible
given that the radiobiology of daily bursts of high dose rate
radiation, given over a number of weeks characteristic of EBRT, is
different to that of RIT. Important key differences between RIT
and EBRT include a lower total dose of radiation, a much lower
dose rate of radiation delivery over prolonged periods of time,
more akin to brachytherapy, and, finally, an exponentially
decreasing dose rate.
In this study, using
131I-labelled A5B7 in nude mice bearing
LS174T xenografts, the effects of fractionation of RIT have been
investigated comparing tumour growth and toxicity. Previous
work using the F(ab0)2 fragment of A5B7 in the same xenograft
model system, comparing single administration of antibody
with the administration of the same activity as three separate
fractions, demonstrated reduced efficacy as a result of fractiona-
tion (Pedley et al, 1993). Similarly, in this study, fractionation
appeared to have a clear detrimental effect upon long-term cure
of tumours. Cures were seen in five out of six animals receiving
the single fraction therapy and two out of six animals receiving
a bi-fractionated administration, whereas no cures were seen in
either the three or four fraction groups.
These findings are at odds to a number of preclinical studies that
have suggested that fractionation of RIT is beneficial, with
improvements in therapeutic effect even in the absence of dose
escalation (Schlom et al, 1990; Buchsbaum et al, 1995; Goel et al,
2001; Bloechl et al, 2005a). In a recent study, looking at
fractionated intraperitoneal RIT in a murine gastric cancer tumour
model, a clear therapeutic advantage was seen following fractiona-
tion. In this study, which used a
213Bi-labelled antibody, the
administration of two injections of antibody at a 7-day interval was
more effective than a single injection of twice the activity (Bloechl
et al, 2005b). The factors that may be responsible for this increase
in therapeutic efficacy have been reviewed and include a
significant ‘inverse dose rate’ effect, increased tumour shrinkage
during therapy leading to improved tumour blood flow, a
reduction in tumour interstitial pressure improving the access of
subsequently therapy doses, and, in addition, an increased time for
tumour re-oxygenation to occur (DeNardo et al, 2002). Pre-clinical
studies have also demonstrated that fractionated RIT improves the
delivery of antibody to the well vascularised, actively growing areas
of tumour (Roberson et al, 1997; Buchsbaum et al, 1999).
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5 mononuclear cells
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sOne possible explanation for the discrepancy seen with some of
the published data in this area is that the total dose of radiation
delivered to tumour sites in our fractionated regime was less than
that achieved by a single administration. Modest reductions in
CEA binding of A5B7 over the course of therapy are evident by day
7 in vitro and may have reduced the efficiency of targeting, hence
reducing the total dose. Furthermore, there were also modest falls
in radiopharmaceutical purity, with a progressive decrease in the
proportion of bound to free antibody over the course of
administration, something that may also be expected to reduce
the tumour-absorbed dose. However, the size of these changes
appears modest in comparison with the difference in tumour
control seen in the study. In addition, reduced vascular perme-
ability as a result of prior radiation exposure has also been noted
7–21 days after RIT in other tumour model systems, and has been
found to lead to reductions in tumour uptake of a second dose of
radiolabelled antibody (Blumenthal et al, 1991, 1995). Although
such changes are tumour-type dependent, the LS174T xenograft
has demonstrated a reduced vascular permeability as a result of
RIT (Blumenthal et al, 1997). Finally, conventional radiobiology
and application of the linear quadratic model predict that
radiation is less effective as the dose rate is lowered due to repair
of sublethal damage requiring a higher total dose for similar effect
(Dale, 1985, 1996; Langmuir and Sutherland, 1988; Fowler, 1990).
In addition, the longer overall treatment times associated with
fractionated RIT will allow greater tumour repopulation during
therapy.
In terms of systemic toxicity, this appeared to be reduced as
a result of fractionation. No significant reductions in acute
haematological toxicity or CFUgm counts were seen, although a
nonsignificant trend towards lower CFUgm counts in each of the
therapy groups compared with their controls was seen, suggesting
that the lack of significance reflected the relatively small number of
data points. The therapy group data were therefore pooled and a
subsequent comparison of treated and untreated animals did
indeed demonstrate a significant depression of CFUgm function as
a result of therapy. The apparent lack of reduction in haemato-
logical toxicity by fractionation could be explained by the low rates
of radiation delivery by RIT, meaning therapy is already highly
fractionated and that any further benefits in terms of normal tissue
sparing resulting from further fractionation are likely to be
minimal (Dale, 1996). In addition, red marrow and its progenitor
cells are known to behave as early responding tissues with limited
repair capacity. As a result, fractionation might be expected
to make little difference to toxicity (Hendry and Lajtha, 1972;
Chu-Tse and Lajtha, 1975).
The findings in this study are similarly at odds with other pre-
clinical studies using colorectal xenografts, which have suggested
that fractionated approaches may be less myelotoxic than single
therapy regimes (Schlom et al, 1990; Beaumier et al, 1991;
Vriesendorp et al, 1993). In the study by Beaumier et al (1991),
delayed and incomplete recovery of WBC counts was seen after
single administration of therapy, whereas this was not seen after
the administration of a multifraction regime of equivalent
administered activity. In the study by Schlom et al (1990), marrow
aplasia resulted from a single administration of radiolabelled
antibody, whereas animals receiving the equivalent administered
activity in a fractionated manner avoided this complication.
However, the most comprehensive study of the effects of
fractionated RIT on haematological toxicity has been undertaken
in non-tumour-bearing animals (Vriesendorp et al, 1993). Acute
haematological toxicity was assessed by daily blood counts, and
an assessment of late marrow toxicity made by assaying early
marrow progenitor cells using CFUgm assays. They found that
single injections of RIT were associated with earlier and more
severe haematological toxicity (thrombocytopenia and granulocy-
topenia) and lower bone marrow CFUgm counts. However, an
important difference between this study and other pre-clinical
studies is that the majority of these have myeloablative activities of
radiation, and then derived fractionated therapy schedules from
this. Published data on the behaviour of marrow progenitor cells
have shown that they have a high ability to repopulate as long as
marrow ablation does not occur (Hendry and Lajtha, 1972; Testa
et al, 1974; Chu-Tse and Lajtha, 1975; Hendry and Lord, 1983), and
the total dose of radiation used in this study was not myeloablative
when given as a single dose.
CONCLUSIONS
In this tumour model system, for a fixed administered activity,
fractionating RIT reduced efficacy. Fractionation was not asso-
ciated with any reduction in either acute blood toxicity or early
marrow progenitor cell function, although the latter was reduced
in treated animals compared with controls. However, systemic
toxicity, as assessed by weight, was reduced.
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